Abstrait
Ľinsuffisance cardiaque a longtemps été considérée comme une altération principale de la contractilité. Les principaux médicaments utilisés jusqu’à aujourďhui font partie de la classe des médicaments inotropes positifs. Ce sont les catécholamines et les inhibiteurs de la phospodiestérase. Ces médicaments inotropes positifs ont pour principales caractéristiques ďaugmenter la concentration cytoplasmique en adénosine monophosphate cyclique (AMPc) dans les myocytes cardiaques. Ľaugmentation ďAMP cyclique va entraîner une augmentation de la concentration intracellulaire de calcium et donc de la force contractile. Le levosimendan est une nouvelle molécule qui augmente la contractilité myocardique en améliorant la réponse des myofilaments au calcium intracellulaire et qui parallèlement ouvre les canaux potassiques ATP-dépendants (KATP) des vaisseaux artériels.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
Références
Mebazaa A et Erhardt L (2003) Levosimendan: a new dual-action drug in the treatment of acute heart failure. International Journal of Clinical Practice. 57: 410–6
Toller WG, Stranz C (2006) Levosimendan, a new inotropic and vasodilator agent. Anesthesiology. 104: 556–69
Ng TM, Singh AK, Dasta JF et al. (2006) Contemporary issues in the pharmacologic management of acute heart failure. Crit Care Clin. 199–219
Follath F, Cleland JGF, Just H et al. (2002) Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 360: 196–202
Moiseyev VS, Poder P, Andrejevs N et al. (2002) RUSSLAN Study Investigators. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 23: 1422–32
Labriola C, Siro-Brigiani M, Carrata F et al. (2004) Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther. 42: 204–11
Lilleberg J, Nieminen M, Akkila J et al. (1998) Effects of a new calcium sensitiser, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilisation early after coronary artery bypass grafting. Eur Heart J. 19: 660–8
Mebazaa A, Karpati P, Renaud E, Algotsson L (2004) Acute right ventricular failure Intensive Care Med. 30: 185–96
Delle Karth G, Buberl A, Geppert A et al. (2003) Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Aneasthesiol Scand. 47: 1251–6
Benlolo S, Lefoll C, Katchatouryan V et al. (2004) Successful use of levosimendan in a patient with peripartum cardiomyopathy. Anaest Analg. 98: 822–4
Nieminen, M. Bohm, M. Cowie et al. (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 26: 384–416
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag France
About this chapter
Cite this chapter
Barraud, D., Farhat, I., Mebazaa, A. (2006). Les sensibilisateurs calciques. In: L’insuffisance cardiaque aiguë. Le point sur.... Springer, Paris. https://doi.org/10.1007/978-2-287-34066-6_15
Download citation
DOI: https://doi.org/10.1007/978-2-287-34066-6_15
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-34065-9
Online ISBN: 978-2-287-34066-6